

# Martha Grogan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3612538/publications.pdf>

Version: 2024-02-01

33  
papers

6,107  
citations

394286

19  
h-index

414303

32  
g-index

33  
all docs

33  
docs citations

33  
times ranked

4173  
citing authors

#	ARTICLE	IF	CITATIONS
1	18F-FDG/13N-ammonia cardiac PET findings in ATTR cardiac amyloidosis. <i>Journal of Nuclear Cardiology</i> , 2023, 30, 726-735.	1.4	4
2	Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary. <i>Future Cardiology</i> , 2022, 18, 165-172.	0.5	2
3	Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 156-164.	1.4	5
4	Non-cardiac biopsy sites with high frequency of transthyretin amyloidosis. <i>ESC Heart Failure</i> , 2021, 8, 750-755.	1.4	7
5	Artificial Intelligence-Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2768-2778.	1.4	40
6	Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1267.	3.0	66
7	Monitoring Tafamidis, The Most Expensive Cardiac Medication. <i>JACC: CardioOncology</i> , 2021, 3, 587-589.	1.7	0
8	Amyloidosis in surgically resected atrial appendages: a study of 345 consecutive cases with clinical implications. <i>Modern Pathology</i> , 2020, 33, 764-774.	2.9	7
9	The Challenges in Chemotherapy and Stem Cell Transplantation for Light-Chain Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 384-395.	0.8	8
10	A Proteomic Atlas of Cardiac Amyloid Plaques. <i>JACC: CardioOncology</i> , 2020, 2, 632-643.	1.7	20
11	Metastatic Merkel Cell Carcinoma Resulting in Complete Heart Block. <i>JACC: CardioOncology</i> , 2020, 2, 131-134.	1.7	1
12	Myocardial Stiffness by Intrinsic Cardiac Elastography in Patients with Amyloidosis: Comparison with Chamber Stiffness and Global Longitudinal Strain. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 958-968.e4.	1.2	22
13	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. <i>Circulation: Heart Failure</i> , 2019, 12, e006075.	1.6	312
14	Contemporary Imaging Diagnosis of Cardiac Amyloidosis. <i>Journal of Cardiovascular Imaging</i> , 2019, 27, 1.	0.2	26
15	Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 589-597.	1.2	116
16	Transthyretin Amyloid Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2872-2891.	1.2	573
17	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.	2.0	17
18	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 455-464.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis. <i>Transplantation</i> , 2018, 102, 1909-1913.	0.5	18
20	MRI feature tracking strain is prognostic for all-cause mortality in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 101-108.	1.4	16
21	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. <i>New England Journal of Medicine</i> , 2018, 379, 1007-1016.	13.9	1,558
22	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	0.6	249
23	Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. <i>Heart</i> , 2017, 103, 1065-1072.	1.2	148
24	Prognosis of Light Chain Amyloidosis With Preserved LVEF. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 398-407.	2.3	83
25	LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 680-686.	2.3	68
26	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. <i>Circulation</i> , 2016, 133, 2404-2412.	1.6	1,335
27	Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1014-1020.	1.2	460
28	Natural history and therapy of AL cardiac amyloidosis. <i>Heart Failure Reviews</i> , 2015, 20, 155-162.	1.7	91
29	Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 2014, 113, 1723-1727.	0.7	112
30	Advanced Cardiac Amyloidosis Associated with Normal Interventricular Septal Thickness: An Uncommon Presentation of Infiltrative Cardiomyopathy. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 440-447.	1.2	30
31	Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2010, 3, 155-164.	2.3	431
32	Echocardiographic features of cardiac amyloidosis presenting as endomyocardial disease in a 54-year-old male. <i>Journal of Cardiology</i> , 2009, 54, 162-166.	0.8	3
33	Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. <i>American Journal of Cardiology</i> , 2005, 95, 535-537.	0.7	263